Lipocine appoints Michael Grissinger to board of directors

Lipocine Inc.

Grissinger appointed as independent director effective August 3, 2026.
Receives initial option grant of 2,000 shares and annual retainer of $55,000.
Over 20 years at Johnson & Johnson in licensing and corporate development roles.
Currently serves on boards of Aprea Therapeutics (APRE) and Adicet Bio (ACET).
Chairman cites his dealmaking experience to advance pipeline and partnerships.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Grissinger

director

LPCN · Lipocine Inc.

Effective: 2026-08-03
Filed: August 3, 2026, 9:35 AM ET

On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Grissinger was appointed as director at Lipocine Inc..

Action: appointed
Role: director

Exact text from the filing

On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.

View on SEC.gov

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-035762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.